



PRO INSTRUMENTS USED IN STUDIES OF BIPOLAR DISORDER SINCE 1960

Alison Martin¹ ¹Crystallise Ltd, Essex, UK alison.martin@crystallise.com

Objectives

To create an evidence map of the different patient-reported outcome instruments used in studies of patients with bipolar disorder, the geographical settings in which these studies were conducted and the interventions assessed.

Methods

We searched the heoro.com database (www.heoro.com) for PRO studies on bipolar disorder published between 1960 and 16 December 2016, and analysed the abstracts identified by the search to determine the different PRO instruments cited across the range of geographical locations and interventions. We presented the findings as an evidence map.

Results

	Geographical jurisdiction													
	Australia	Brazil	Canada	Chile	Czech Republic	Denmark	France	Germany	India	International or unknown	Italy	Korea		
No. of studies	6	6	7	1	1	1	3	2	1	8	7	2		

	Netherlands	Nigeria	Norway	Saudi Arabia	Spain	Switzerland	Taiwan	Thailand	Turkey	UK	US	
No. of studies	2	1	1	1	6	2	2	1	2	8	56	

	PRO Instrument																
	ASI Addiction Severity Index	BAI Beck Anxiety Inventory	BAS Caregiver burden scale	BDI Beck Depression Inventory	BDQ Brief Disability Q'nnaire	BPRS Brief Psychiatric Rating Scale	CES-D Center for Epidemio-logical Studies- Depression	CFS Cognitive Function Scale	CGAS Children's Global Assessment Scale	CGI-BP Clinical Global Impression for Bipolar Disorder	CGI-S Clinical Global Impression- Severity of Illness	CHQ Child Health Q'nnaire	CIDI Composite International Diagnostic Interview	CODS Consequences of Depression Scale	CORE-OM Clinical Outcomes in Routine Evaluation - Outcome Measure	CTD Cognitive Test for Delirium	CUDOS Clinically Useful Depression Outcome Scale
No. of studies	1	1	1	1	1	2	1	1	1	7	3	3	2	1	1	1	1
	DAI-10, DAI-30 Drug Attitude Inventory	EQ-5D EuroQol 5 item scale	EWPS Endicott Workplace Productivity Scale	FAST Functioning Assessment Short Test	GAD-7 Generalised Anxiety Disorder Assessment	GAF Global Assessment of Functioning	GAS Global Assessment Scale	GDS Geriatric Depression Scale	GHQ-12 General Health Q'nnaire	HADS Hospital Anxiety and Depression Scale	HAM-A Hamilton Anxiety Rating Scale	HAM-D Hamilton Depression Rating Scale	HoNOS Health of the Nation Outcome Scales	HWPQ WHO Health and Work Performance Q'nnaire	IDS-C30 Inventory of Depressive Symptomatol ogy-Clinician- Rated	IIRS Illness Intrusiveness Rating Scale	IPAQ Impact on Participation and Autonomy Q'nnaire
No. of studies	3	7	1	1	2	5	1	1	1	1	4	15	1	1	2	1	1
	ISS Internal State Scale	IWQOL- Lite Impact of Weight on Quality of Life-Lite	KINDL-R Revised Children Quality of Life Q'nnaire	LIFE-RIFT Longitudinal Interval Follow- up Evaluation- Range of Impaired Functioning	LLE List of Life Events	LSP Life Skills Profile	MADRS Montgomery Asberg Depression Rating Scale	Mastery Scale	MARS Medication Adherence Rating Scale	MDQ Mood Disorder Q'nnaire	MHI-17 Mental Health Index-17	MINI Mini International Neuropsych- iatric Interview	MMPI Minnesota Multiphasic Personality Inventory	MRTF Medication Recommendation Tracking Form	MSQ Mood Swings Q'nnaire	MSS Mood Spectrum Self-Report	NEO-5 NEO Five- Factor Personality Inventory
No. of studies	2	1	1	5	1	1	13	1	1	5	1	1	1	1	2	1	1
	OCDS Obsessive Compulsive Drinking Scale	OPQ Occupational Performance Q'nnaire	PANSS Positive and Negative Syndrome Scale	PCASEE Q'nnaire	PGWB Psychologica I General Well-Being	PHQ-9 Patient Health Q'nnaire	PREDIMED Mediterranean Diet Q'nnaire	PRISE Patient Rated Inventory of Side Effects	PSPS Personal and Social Performance Scale	PSQI Pittsburgh Sleep Quality Index	QIDS-16 Quick Inventory of Depressive Symptoms	QLDS Quality of Life in Depression Scale	Q-LES-Q Quality of Life Enjoyment and Satisfaction Q'nnaire	QLI Lehman Brief Quality of Life Interview	QWB Quality of Well-Being scale	RSES Rosenberg's Self-Esteem Scale	SADS Schedule for Affective Disorders and Schizophrenia
No. of studies	1	1	2	1	3	3	1	1	1	6	1	3	17	3	1	1	2
	SAFTEE Q'nnaire	SBQOL SmithKline Beecham Quality of Life Q'nnaire	SCID Structured Clinical Interview for DSM	SCI- MOODS Q'nnaire	SDS Sheehan Disability Scale	SF-6D Short-form-6 items	SF-12 Short-form-12 items	SF-36 Short-form- 36 items	SG Standard Gamble	SMAQ Simplified Medication Adherence Q'nnaire	TCAS Therapeutic Community Assessment scale	ToOL Tolerability and Quality of Life Q'nnaire	TRQ Tablet Routine Q'nnaire	UKU Udvalg for Kliniske Undersogelser	WHOQOL- BREF WHO Brief Quality of Life Scale	YMRS Young Mania Rating Scale	
No. of studies	1	1	4	1	3	2	10	26	1	1	1	1	1	1	10	18	

	Interventions														
	Psychological therapy, general	СВТ	Dialectical behavioural therapy	Psycho- education	Self- management	Drug therapy, general	Aripiprazole	Armodafinil	Asenapine	Divalproex	Duloxetine	Fluoxetine	Haloperidol		
No. of studies	3	6	1	6	2	3	1	1	1	1	1	1	2		
	Imipramine	Lamotrigine	Lithium	Olanzapine	Quetiapine	Risperidone	Valproic acid	Venlafaxine	Ziprasidone	Zonisamide	Lifestyle	Housing	Other therapy		
No. of studies	1	2	5	11	6	3	2	1	1	1	2	2	2		

		Ty	ype of F	PRO ass	sessme			Publi	cation	year			
	General QOL	Utility	Disease- specific	Comorbidity	Work	Medication	Caregiver		1960-1999	2000-2004	2005-2009	2010-2014	2015-2016
No. of studies	46	41	58	15	3	9	1	No. of studies	7	24	48	40	9

Numbers refer to number of studies identified for each category. Where a study is set in two or three locations, these are all listed separately. Studies set in five or more jurisdictions, or systematic reviews are classified as International. Studies are mapped to all relevant subcategories. Number of studies in each subgroup may not add up to the total score because of double-counting.

Conclusions

A wide range of PRO tools have been used in studies of bipolar disorder, but only ten tools were cited in more than five abstracts each. Research into the quality of life in bipolar disorder has generally been assessed from a US perspective.

Crystallise Ltd. Unit 21 Thames Enterprise Centre, Thames Industrial Park, East Tilbury, Essex RM18 8RH , UK **Tel**: +44 (0)1375 488020

For a copy of this poster or the detailed evidence map, email: alison.martin@crystallise.com



Presented at the ISPOR 22nd Annual Congress 20-24 May 2017, Boston, US

www.crystallise.com www.heoro.com